📬 GYN Oncology Intelligence Digest — Week 2026-W29

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy. — Powell Matthew A et al., Int J Gynecol Cancer

In the overall population, the risk of progression or death was significantly reduced by 40% (hazard ratio 0.60, 95% confidence interval 0.43 to 0.82, p <.001) with niraparib added to dostarlimab maintenance. At 36.2 months of follow-up, no overall survival benefit was observed with niraparib+dostarlimab versus the control (hazard ratio 1.2, 95% confidence interval 0.81 to 1.78). Grade ≥3 treatment-related adverse events occurred in 70.7% of patients in the niraparib+dostarlimab arm and 37.5% in the control arm.

Clinical bottom line: Adding niraparib to dostarlimab maintenance improved PFS but conferred no OS benefit and substantially more toxicity, so dostarlimab maintenance alone remains the only regimen with a proven OS advantage in this setting.

Read full article →

Maintenance therapy in gynecologic malignancies: Current and future state. — Widick Page C et al., Cancer

Maintenance agents including VEGF and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have improved PFS and sometimes even OS among women with ovarian cancer when used as monotherapy or in combination. In endometrial and cervical cancers, immune checkpoint inhibitors combined with chemotherapy and used as maintenance thereafter have improved PFS and OS.

Clinical bottom line: This review restates that maintenance with VEGF, PARP, and checkpoint inhibitors improves PFS and sometimes OS across gynecologic cancers, but must be weighed against toxicity and financial cost.

Read full article →

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program. — Domènech Heura et al., NPJ Precis Oncol

HRD was more frequent in high-grade ovarian cancer (52%) than in metastatic breast cancer (12%) or prostate cancer (20%). Longitudinal ctDNA sequencing revealed BRCA1/BRCA2 reversion mutations in >30% of post-PARPi metastatic breast cancer samples, which were associated with poor response to subsequent platinum therapy.

Clinical bottom line: Complementary HRD biomarkers in tissue and liquid biopsy, including RAD51 testing and genomic instability score, detect HRD missed by genetic testing and can monitor PARPi resistance via ctDNA reversion mutations.

Read full article →

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial. — Salutari Vanda et al., Int J Gynecol Cancer

Complete pathological response was achieved in three patients (8.6%), while the overall response rate was 89%, assessed at the completion of neoadjuvant treatment prior to interval debulking surgery. Median progression-free survival was 39.7 months (95% confidence interval 22.4 to not reached), while median overall survival was not reached (95% confidence interval 47.6 to not reached) at 42.9 months median follow-up.

Clinical bottom line: Concurrent intermittent olaparib with neoadjuvant chemotherapy did not increase complete pathological response in BRCA-mutated ovarian cancer, suggesting PARP inhibitor benefit is driven by post-chemotherapy maintenance rather than concurrent neoadjuvant use.

Read full article →